finviz

Adobe reported the weakest revenue growth since 2015 of the year

22 March Adobe reported for the first quarter of 2022, which ended 4 Martha. The results were slightly better than expected., but the forecast for the current quarter fell short of analysts' estimates. Results Adobe's first fiscal quarter this year was a week shorter, than in the past.

The Money Cow Index Outperformed the S&P 500 for the latest 12 Months

Since the beginning of 2022, growth shares from S&P 500 far behind value stocks: −5% vs. +1,2%. Expecting Fed rate hike, investors are shifting from overvalued companies to more reliable ones. For example, in "cash cows". What are "cows"? Cash Cows - Companies from the Pacer US Cash Cows Fund.

Gossamer Bio Review: not "goose", a biotech

Gossamer Bio (NASDAQ: GOSS) - a young biotech company from California. The business was founded in 2015 and went public in 2019 through a nasdaq offering. The company focuses on the development of drugs in the field of immunology, oncology and therapy of inflammatory processes.

Heron Therapeutics Review: solutions for oncology and postoperative recovery

Heron Therapeutics (NASDAQ: HRTX) - San Diego-based biotechnology company, founded in the USA in 1983. Business is focused on helping patients, undergoing chemotherapy, and relief of postoperative pain. In the distant past, the company's shares were more expensive 1000 $ for pike, and now dropped to 10-12 $. Where the money comes from Commercial business strategy is focused on addressing the unmet needs of different groups of patients and is now engaged in research in the field of oncology and surgery.. The company has already brought several drugs to the U.S. market to relieve postoperative pain and relieve symptoms., caused by different courses of chemotherapy. Product Development Portfolio To date, Heron Therapeutics has successfully commercialized three of its products. Zynrelef. For the first time 72 hours relieves pain in adult patients, who have undergone major knee surgery. Approved by the Food and Drug Administration (FDA) 1 July 2021 and became an alternative to traditional opioids, the use of which is associated with the risk of addiction. Approved in 31 European country. Cinvanti and Sustol. Drugs for adult patients with cancer. Prevents nausea & vomiting, caused by the passage of primary and repeated courses of chemotherapy of varying degrees of aggressiveness. The company has two drugs for adults at the clinical stage of development: HTX-034 to relieve postoperative pain in the first 5-7 days and HTX-019, which prevents bouts of nausea and vomiting in patients, who have undergone surgery. For the latter, it is planned to apply for FDA approval in the fourth quarter of 2021.. Что плохого Коронавирус наносит ответный удар. Last year, the pandemic and lockdowns significantly hurt the company's business.: medical facilities were closed and patients simply could not get their appointments from doctors., prescription drug manufacturers suffered losses. Сейчас ситуация с вакцинацией и мерами профилактики …

Heron Therapeutics Review: solutions for oncology and postoperative recovery Read more

Обзор Intercept Pharmaceuticals: so that the liver does not hurt

Intercept Pharmaceuticals (NASDAQ: ICPT) - a biotechnology company from the USA, which in her research focuses on solving the problems of liver diseases. The business was founded in 2002 and listed its shares on the Nasdaq in 2012 - now they are trading close to the all-time low in the area 15 $. Where does the money come from? Like most biotechs, the company develops medicines and prepares them for commercialization in the US markets, Canada and Europe. Intercept Pharmaceuticals plans to produce synthetic analogs of bile acids, which will be used in the treatment of chronic liver diseases, such as primary biliary cholangitis, non-alcoholic steatohepatitis, cirrhosis of the liver and others. Portfolio of developed drugs The main developments of the company are based on obeticholic acid (OCA). The drug "Okaliva" based on it was approved by the Food and Drug Administration (FDA) in May 2016 and is prescribed by prescription for the treatment of primary biliary cholangitis. Intercept Pharmaceuticals plans to expand its sales market: filed for FDA approval for fibrosis, associated with non-alcoholic steatohepatitis; the third phase of clinical trials of the drug for use in the treatment of cirrhosis is underway, caused by non-alcoholic steatohepatitis; the second phase of clinical trials is underway for the combination of obeticholic acid and bezofibrate in the treatment of primary biliary cholangitis. The company has also begun preclinical development of a new generation of farnesoid receptor agonists. (FXR). Что плохого Объем коротких позиций в акциях компании, по данным Finviz, exceeds 30%, which puts strong pressure on prices, which have reached historic lows this year. Commitments have been growing since 2019 and as of August 2021 are 139% from business assets. The greater the debt, тем больше денег будет уходить на его обслуживание — в случае повышения процентной ставки …

Обзор Intercept Pharmaceuticals: so that the liver does not hurt Read more

1001 useful resource for the USA trader

Nowadays, the World Wide Web takes pride of place in everyone's life.. And of course, Internet resources are another good helper for a trader, both at the training stage, and throughout the entire activity. Agree, after all, we often turn to Google for tips.

ETF & STOCKS FOR LONG-TERM DIVIDEND PORTFOLIO

Hello, dear friends! Earlier, I devoted a fairly extensive material to ETFs and issues, related to their selection, portfolio formation and the principle of work in general. Today, the focus will be on that, how to buy shares for an individual and receive dividends. I wrote about the purchase of shares by individuals in one of the materials, I recommend that you familiarize yourself with it. I would like to remind you in advance, that diversification is important when forming an investment portfolio. That is, you need to include different tools in its composition.: along with conventional ETFs and dividends, as well as special funds.  

Stock Reporting Season ( Earnings Season ) – 14 useful tips

Earnings Season (Reporting season ) provides us with most of the opportunities for profitable trades. This is our final series of games. It looks like Opening, repeated every day for six weeks and four times a year. Every day is new. Every day is special. Every day is delicious. Every day offers tremendous opportunities. This is our favorite time to trade. Below are some suggestions for, to help you maximize these opportunities during this Earnings .

Scroll to Top